April 29, 2016
The drug is indicated to treat high triglycerides, dysbetalipoproteinemia and high LDL cholesterol. It was approved in 5-, 10, 20-, and 40-mg dosage strengths, according to the FDA. 
April 27, 2016

 On Tuesday, the FDA approved Aurobindo’s generic Exforge (amlodipine and valsartan) tablets, and on Wednesday gave its OK to the company’s generic Opana (oxymorphone HCl) and Pepcid AC (famotidine). 

April 26, 2016

The researchers are currently conducting a National Health and Medical Research Council study using a combination of these nutraceuticals for depression.

April 26, 2016

A new partnership between the two companies will see development and commercialization of generics with a high technological barrier. 

April 25, 2016

The drug had an estimated market size of about $4.2 billion for the 12 months ending February 2016, according to IMS Health. 

April 25, 2016

Perrigo's new CEO led the company's U.S. Consumer Healthcare business from 2003 to 2006

April 22, 2016
The drug had U.S. sales of about $39 million for the 12 months ended December 2015, according to IMS Health. 
 
April 15, 2016

A new bill looks to push the FDA into rewriting a guidance on generic drug and biosimilar naming by withholding funding unless it meets Congress’ requests. 

April 14, 2016

In 2015, the OGD granted 580 approvals and 146 tentative approvals, including 99 in December alone – the largest number of drug approvals given out in a single month. 

April 13, 2016

The legislation, advocated by both retail pharmacy and the pharma industry, would advance collaboration among health and enforcement authorities to achieve drug abuse solutions that maintain patients’ legitimate access to medications.

April 12, 2016

A new report from Accenture is shedding light on a new focus on the part of pharmaceutical companies: investing in patient-centered capabilities and services.

April 12, 2016

The company said it uses web-based pharmacy benefit system MERLIN, which has 16 integrated modules that can aid in personalizing service for each client.

April 11, 2016

California pharmacists are authorized to furnish oral, transdermal, vaginal and Depo injection forms of prescription birth control under a new law that took effect April 8. 

April 11, 2016

The launch makes Mylan the only manufacturer with five strengths for its generic Lopressor, a treatment for hypertension.

April 11, 2016

When implementation of Walgreens' naloxone program is complete, naloxone will be available without a prescription in more than 5,800 of Walgreens nearly 8,200 stores.

April 7, 2016

 The drug is indicated to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome, as well as to prevent CMV in high-risk kidney, heart, or kidney-pancreas transplant.

April 7, 2016

Lamivudine tablets had U.S. sales of about $27.1 million for the 12 months ended December 2015.

April 7, 2016

The letter points out that copay increases place financial burdens on TRICARE beneficiaries and restrict patient access. In addition, restricting patient access could adversely impact medication compliance and actually increase health costs. 

April 7, 2016

So far in 2016, there have been multiple Part D plans and PBMs that have been utilizing MAC drug pricing values that are "far below what would be considered to be reasonably approaching market prices for drugs," the letter noted.

April 6, 2016

Lupin on Wednesday announced the appointment of Dr. Kurt Nielsen as president of Lupin-Somerset.

April 6, 2016
Lupin received final approval for Zolpidem Sublingual Tablets from the United States Food & Drug Administration earlier, as well as final clearance from the FTC with 180 days of exclusivity.
 
April 6, 2016

Hospira, now a Pfizer company, entered into an agreement with Celltrion and Celltrion Healthcare in 2009 for several potential biosimilar products, including the recently-approved Inflectra.

April 5, 2016
ANI Pharmaceuticals on Tuesday announced the Food and Drug Administration approval for one new generic and the launch of another. 
April 5, 2016

Global Citizen is reporting that GlaxoSmithKline will be granting licenses to generics manufacturers in lower middle-income countries in a move aimed at increasing access to medicine in low-income countries. The company announced the changes at the end of March, noting that rather than attempting to enforce its patents, it would move to a licensing model, charging a small fee to generics manufacturers. (Global Citizen)